{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:23:46Z","timestamp":1794774226296,"version":"4.9.1"},"reference-count":182,"publisher":"Elsevier","isbn-type":[{"value":"9780443297021","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.acc.2024.04.005","type":"book-chapter","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:01:16Z","timestamp":1714060876000},"page":"89-131","source":"Crossref","is-referenced-by-count":18,"title":["suPAR in cardiovascular disease"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2024.04.005_bib1","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00134-012-2613-1","article-title":"Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review","volume":"38","author":"Backes","year":"2012","journal-title":"Intensive Care Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib2","first-page":"265","article-title":"suPAR: an Inflammatory Mediator for Kidneys","volume":"8","author":"Sudhini","year":"2022","journal-title":"Kidney\u00a0Dis."},{"key":"10.1016\/bs.acc.2024.04.005_bib3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2011.10.039","article-title":"Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malm\u00f6 Diet and Cancer Study","volume":"220","author":"Persson","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.005_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/med.10054","article-title":"Clinical significance of urokinase\u2010type plasminogen activator receptor (uPAR) expression in cancer","volume":"24","author":"de Bock","year":"2004","journal-title":"Med. Res. Rev."},{"key":"10.1016\/bs.acc.2024.04.005_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/j.1460-2075.1990.tb08132.x","article-title":"Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis","volume":"9","author":"Roldan","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/bs.acc.2024.04.005_bib6","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/S0021-9258(18)69214-2","article-title":"A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification","volume":"263","author":"Nielsen","year":"1988","journal-title":"J. Bio. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1432-1033.1992.tb17200.x","article-title":"A soluble form of the glycolipid\u2010anchored receptor for urokinase\u2010type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria","volume":"208","author":"Ploug","year":"1992","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/bs.acc.2024.04.005_bib8","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1046\/j.1523-1755.2001.00719.x","article-title":"Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia","volume":"59","author":"Florquin","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2024.04.005_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/1523-1747.ep12461511","article-title":"Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo","volume":"90","author":"Gr\u00f8ndahl-Hansen","year":"1988","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2024.04.005_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: the molecular crystal ball","volume":"27","author":"Thun\u00f8","year":"2009","journal-title":"Dis. Markers."},{"key":"10.1016\/bs.acc.2024.04.005_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1160\/TH04-09-0580","article-title":"Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules","volume":"93","author":"Montuori","year":"2005","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2024.04.005_bib12","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1373\/clinchem.2013.203778","article-title":"Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain","volume":"59","author":"Lyngb\u00e6k","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00392-019-01475-1","article-title":"Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction","volume":"108","author":"S\u00f6rensen","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/1354750X.2020.1778090","article-title":"Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes","volume":"25","author":"Peir\u00f3","year":"2020","journal-title":"Biomarkers"},{"key":"10.1016\/bs.acc.2024.04.005_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2016.12.008","article-title":"soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure","volume":"5","author":"Koller","year":"2017","journal-title":"JACC Heart Fail."},{"key":"10.1016\/bs.acc.2024.04.005_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation","volume":"12","author":"Rasmussen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.acc.2024.04.005_bib17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0021-9258(18)52382-6","article-title":"Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol","volume":"266","author":"Ploug","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib18","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1016\/S0021-9258(18)31492-3","article-title":"A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor","volume":"266","author":"Masucci","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0022-1759(94)90078-7","article-title":"Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay","volume":"167","author":"R\u00f8nne","year":"1994","journal-title":"J. Immunol. Methods."},{"key":"10.1016\/bs.acc.2024.04.005_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.1995.tb08366.x","article-title":"The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria","volume":"89","author":"R\u00f8nne","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.acc.2024.04.005_bib21","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/emboj\/16.10.2610","article-title":"Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes","volume":"16","author":"Nykjaer","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/bs.acc.2024.04.005_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-5793(94)00674-1","article-title":"Structure\u2014function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom \u03b1-neurotoxins","volume":"349","author":"Ploug","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.acc.2024.04.005_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrm977","article-title":"uPAR: a versatile signalling orchestrator","volume":"3","author":"Blasi","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/bs.acc.2024.04.005_bib24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/hq0701.093685","article-title":"Role of the\u00a0matrix metalloproteinase and plasminogen activator\u2013plasmin systems in angiogenesis","volume":"21","author":"Pepper","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2024.04.005_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases","volume":"92","author":"Visse","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2024.04.005_bib26","doi-asserted-by":"crossref","first-page":"22885","DOI":"10.1074\/jbc.271.37.22885","article-title":"Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains","volume":"271","author":"Behrendt","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/bs.acc.2024.04.005_bib27","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.2741\/3392","article-title":"Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR","author":"Montuori","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/bs.acc.2024.04.005_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1357-2725(99)00005-9","article-title":"Vitronectin","volume":"31","author":"Schvartz","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/bs.acc.2024.04.005_bib29","doi-asserted-by":"crossref","first-page":"27982","DOI":"10.1074\/jbc.M111736200","article-title":"Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization","volume":"277","author":"Sidenius","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib30","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.15252\/embj.201387611","article-title":"The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins","volume":"33","author":"Ferraris","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/bs.acc.2024.04.005_bib31","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood.V91.7.2305","article-title":"Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes","volume":"91","author":"Chavakis","year":"1998","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2024.04.005_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/bs.acc.2024.04.005_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0300-9475.2005.01547.x","article-title":"Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells","volume":"61","author":"Ostrowski","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/bs.acc.2024.04.005_bib34","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1121143","article-title":"Structure of human urokinase plasminogen activator in complex with its receptor","volume":"311","author":"Huai","year":"2006","journal-title":"Science"},{"key":"10.1016\/bs.acc.2024.04.005_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jmb.2011.12.058","article-title":"Crystal structure of the urokinase receptor in a ligand-free form","volume":"416","author":"Xu","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/bs.acc.2024.04.005_bib36","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1172\/JCI124793","article-title":"UPAR isoform 2 forms a dimer and induces severe kidney disease in mice","volume":"129","author":"Wei","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib37","doi-asserted-by":"crossref","first-page":"33544","DOI":"10.1074\/jbc.M111.220087","article-title":"Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction","volume":"286","author":"G\u00e5rdsvoll","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1515\/BC.2004.031","article-title":"The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP\/ Endo180): membrane proteins engaged in matrix turnover during tissue remodeling","volume":"385","author":"Behrendt","year":"2004","journal-title":"Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/(SICI)1097-4652(199908)180:2<225::AID-JCP10>3.0.CO;2-2","article-title":"Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression","volume":"180","author":"Wilhelm","year":"1999","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib40","doi-asserted-by":"crossref","first-page":"18224","DOI":"10.1016\/S0021-9258(19)37176-5","article-title":"Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain","volume":"267","author":"H\u00f8yer-Hansen","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1432-1033.1997.0021a.x","article-title":"Cell\u2010surface acceleration of urokinase\u2010catalyzed receptor cleavage","volume":"243","author":"H\u00f8yer\u2010Hansen","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/bs.acc.2024.04.005_bib42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1042\/bj3580673","article-title":"Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor","volume":"358","author":"H\u00f8yer-Hansen","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/bs.acc.2024.04.005_bib43","doi-asserted-by":"crossref","first-page":"7279","DOI":"10.1093\/emboj\/16.24.7279","article-title":"A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity","volume":"16","author":"Fazioli","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/bs.acc.2024.04.005_bib44","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1373\/clinchem.2004.038232","article-title":"Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor","volume":"50","author":"Piironen","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib45","first-page":"7126","article-title":"Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy","volume":"60","author":"Mustjoki","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2024.04.005_bib46","first-page":"717","article-title":"Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance","volume":"79","author":"Sier","year":"1999","journal-title":"Lab. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib47","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.172.1.540","article-title":"Proteolytic regulation of the urokinase receptor\/CD87 on monocytic cells by neutrophil elastase and Cathepsin G","volume":"172","author":"Beaufort","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2024.04.005_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11010-008-9925-z","article-title":"Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR\/CD87)","volume":"321","author":"Pliyev","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/bs.acc.2024.04.005_bib49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40560-019-0397-x","article-title":"Neutrophils are a main source of circulating suPAR predicting outcome in critical illness","volume":"7","author":"Gussen","year":"2019","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib50","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/sj.bjc.6605228","article-title":"Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer","volume":"101","author":"Lomholt","year":"2009","journal-title":"Br. J. Cancer."},{"key":"10.1016\/bs.acc.2024.04.005_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cca.2014.10.004","article-title":"Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points","volume":"439","author":"Thurison","year":"2015","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/bs.acc.2024.04.005_bib52","series-title":"Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-70115-4","article-title":"The role of glycosylation in health and disease","author":"Lauc","year":"2021"},{"key":"10.1016\/bs.acc.2024.04.005_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.751637","article-title":"An overview of glycosylation and its impact on cardiovascular health and disease","volume":"8","author":"Loaeza-Reyes","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/bs.acc.2024.04.005_bib54","doi-asserted-by":"crossref","first-page":"13933","DOI":"10.1074\/jbc.273.22.13933","article-title":"Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in chinese hamster ovary cells","volume":"273","author":"Ploug","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib55","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1016\/S0021-9258(19)39348-2","article-title":"The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants","volume":"265","author":"Behrendt","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib56","doi-asserted-by":"crossref","first-page":"11152","DOI":"10.1016\/S0021-9258(18)82104-4","article-title":"N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand","volume":"268","author":"M\u00f8ller","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib57","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/pros.21306","article-title":"Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer","volume":"71","author":"Almasi","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/bs.acc.2024.04.005_bib58","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s12170-018-0579-4","article-title":"Protein N-Glycosylation in cardiovascular diseases and related risk factors","volume":"12","author":"Gudelj","year":"2018","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"10.1016\/bs.acc.2024.04.005_bib59","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V84.4.1151.1151","article-title":"The structure of the urokinase-type plasminogen activator receptor gene","volume":"84","author":"Casey","year":"1994","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2024.04.005_bib60","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1083\/jcb.115.6.1763","article-title":"Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract","volume":"115","author":"Kristensen","year":"1991","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.acc.2024.04.005_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0014-5793(93)81763-P","article-title":"An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator","volume":"326","author":"Pyke","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.acc.2024.04.005_bib62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clinbiochem.2019.05.010","article-title":"Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals","volume":"69","author":"Chew-Harris","year":"2019","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2024.04.005_bib63","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1373\/clinchem.2006.067595","article-title":"Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP Technology","volume":"52","author":"Kofoed","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/172460080101600402","article-title":"Soluble urokinase plasminogen activator receptor measurements: influence of sample handling","volume":"16","author":"Riisbro","year":"2001","journal-title":"Int. J. Biol. Markers."},{"key":"10.1016\/bs.acc.2024.04.005_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jmv.21114","article-title":"Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy","volume":"80","author":"Andersen","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/bs.acc.2024.04.005_bib66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40620-022-01344-7","article-title":"Assay-related differences in SuPAR levels: implications for measurement and data interpretation","volume":"36","author":"Vasbinder","year":"2022","journal-title":"J. Nephrol."},{"key":"10.1016\/bs.acc.2024.04.005_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/00365513.2020.1741674","article-title":"Validation of suPAR turbidimetric assay on Cobas\u00ae (c502 and c702) and comparison to suPAR ELISA","volume":"80","author":"Skovsted","year":"2020","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.talanta.2016.07.004","article-title":"An ELISA method detecting the active form of suPAR","volume":"160","author":"Zhou","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/bs.acc.2024.04.005_bib69","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/clinchem\/43.10.1868","article-title":"ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients","volume":"43","author":"Stephens","year":"1997","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib70","doi-asserted-by":"crossref","first-page":"13783","DOI":"10.1038\/s41598-019-50405-8","article-title":"Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis and impact of detection method","volume":"9","author":"Winnicki","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2024.04.005_bib71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ki.2013.549","article-title":"Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?","volume":"85","author":"Schl\u00f6ndorff","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/bs.acc.2024.04.005_bib72","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1161\/CIRCULATIONAHA.118.036823","article-title":"In aptamers they trust","volume":"138","author":"Joshi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2024.04.005_bib73","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Eugen\u2010Olsen","year":"2010","journal-title":"J. Intern. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib74","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.ijcard.2012.07.018","article-title":"Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score","volume":"167","author":"Lyngb\u00e6k","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ejhf.49","article-title":"Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation","volume":"16","author":"Born\u00e9","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2024.04.005_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-018-0141-8","article-title":"Healthy lifestyles reduce suPAR and mortality in a Danish general population study","volume":"16","author":"Haupt","year":"2019","journal-title":"Immun. Ageing."},{"key":"10.1016\/bs.acc.2024.04.005_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110555","article-title":"Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants","volume":"9","author":"Haastrup","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.04.005_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140052","article-title":"Increased soluble urokinase-type plasminogen activator receptor (suPAR) levels in plasma of suicide attempters","volume":"10","author":"Ventorp","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.04.005_bib79","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ijcard.2012.03.040","article-title":"CRP and suPAR are differently related to anthropometry and subclinical organ damage","volume":"167","author":"Lyngb\u00e6k","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib80","first-page":"91","article-title":"Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population","volume":"2014","author":"Haupt","year":"2014","journal-title":"Biomark. Insights."},{"key":"10.1016\/bs.acc.2024.04.005_bib81","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015457","article-title":"Sex differences in circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels and adverse outcomes in coronary artery disease","volume":"9","author":"Mehta","year":"2020","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/bs.acc.2024.04.005_bib82","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/molehr\/gah081","article-title":"Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle","volume":"10","author":"Nordengren","year":"2004","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/bs.acc.2024.04.005_bib83","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1017\/S0007114518003720","article-title":"Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality","volume":"121","author":"T\u00f6rnkvist","year":"2019","journal-title":"Br. J. Nutr."},{"key":"10.1016\/bs.acc.2024.04.005_bib84","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s42003-021-02144-8","article-title":"Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor","volume":"4","author":"Dowsett","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/bs.acc.2024.04.005_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058506","article-title":"NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study","volume":"8","author":"Kruger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.04.005_bib86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCGEN.121.003421","article-title":"Soluble urokinase plasminogen activator receptor: genetic variation and cardiovascular disease risk in black adults","volume":"14","author":"Olson","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib87","unstructured":"World Health Organization, Cardiovascular diseases. https:\/\/www.who.int\/health-topics\/cardiovascular-diseases\/ (accessed 10.11.23)."},{"issue":"2023","key":"10.1016\/bs.acc.2024.04.005_bib88","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"issue":"2021","key":"10.1016\/bs.acc.2024.04.005_bib89","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2024.04.005_bib90","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.hfc.2009.04.011","article-title":"What we may expect from biomarkers in heart failure","volume":"5","author":"Richards","year":"2009","journal-title":"Heart Fail. Clin."},{"key":"10.1016\/bs.acc.2024.04.005_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc11434","article-title":"Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study","volume":"16","author":"Haupt","year":"2012","journal-title":"Crit. Care."},{"key":"10.1016\/bs.acc.2024.04.005_bib92","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijcard.2015.03.041","article-title":"Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population","volume":"184","author":"Botha","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib93","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/emermed-2015-205444","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study","volume":"33","author":"Rasmussen","year":"2016","journal-title":"Emerg. Med. J."},{"key":"10.1016\/bs.acc.2024.04.005_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc10037","article-title":"Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients","volume":"15","author":"Koch","year":"2011","journal-title":"Crit. Care."},{"key":"10.1016\/bs.acc.2024.04.005_bib95","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1478-3231.2011.02665.x","article-title":"Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis","volume":"32","author":"Zimmermann","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/bs.acc.2024.04.005_bib96","first-page":"686","article-title":"The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau","volume":"6","author":"Eugen-Olsen","year":"2002","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/bs.acc.2024.04.005_bib97","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.qai.0000157950.02076.a6","article-title":"High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of morality in HIV-1-infected patients","volume":"39","author":"Ostrowski","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/bs.acc.2024.04.005_bib98","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2011.10.044","article-title":"The urokinase system in the pathogenesis of atherosclerosis","volume":"222","author":"Fuhrman","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.005_bib99","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.mbc.0000114441.59147.56","article-title":"Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions","volume":"15","author":"Steins","year":"2004","journal-title":"Blood Coagul. Fibrinolysis."},{"key":"10.1016\/bs.acc.2024.04.005_bib100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.ATV.15.1.37","article-title":"Augmented urokinase receptor expression in atheroma","volume":"15","author":"Noda-Heiny","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1970","key":"10.1016\/bs.acc.2024.04.005_bib101","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1161\/STROKEAHA.112.664094","article-title":"Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque","volume":"43","author":"Edsfeldt","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/bs.acc.2024.04.005_bib102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2014.12.025","article-title":"Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease","volume":"239","author":"Mekonnen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.005_bib103","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009881","article-title":"Local production of soluble urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in the coronary circulation is associated with coronary endothelial dysfunction in humans","volume":"7","author":"Corban","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/bs.acc.2024.04.005_bib104","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3899\/jrheum.110006","article-title":"Low-grade chronic inflammation and vascular damage in patients with rheumatoid arthritis: don\u2019t forget \u201cmetabolic inflammation\u201d","volume":"38","author":"Jeppesen","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/bs.acc.2024.04.005_bib105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2014.08.035","article-title":"Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects","volume":"237","author":"S\u00f8rensen","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.005_bib106","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001118","article-title":"Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events","volume":"3","author":"Eapen","year":"2014","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/bs.acc.2024.04.005_bib107","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/1873-3468.14305","article-title":"Soluble forms of cytokine and growth factor receptors: mechanisms of generation and modes of action in the regulation of local and systemic inflammation","volume":"596","author":"Kefaloyianni","year":"2022","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.acc.2024.04.005_bib108","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.2741\/3550","article-title":"The urokinase receptor as an entertainer of signal transduction","volume":"14","author":"D\u2019Alessio","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/bs.acc.2024.04.005_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086352","article-title":"The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface","volume":"9","author":"Gorrasi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.04.005_bib110","first-page":"459","article-title":"Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis","volume":"22","author":"Svensson","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib111","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/j.1460-2075.1996.tb00502.x","article-title":"Proteolytic cleavage of the urokinase receptor substitutes for the agonist\u2010induced chemotactic effect","volume":"15","author":"Resnati","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/bs.acc.2024.04.005_bib112","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V94.2.649","article-title":"Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells","volume":"94","author":"Degryse","year":"1999","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2024.04.005_bib113","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijcard.2011.12.094","article-title":"Urokinase receptor surface expression regulates monocyte migration and is associated with accelerated atherosclerosis","volume":"161","author":"Chen","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib114","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1091\/mbc.12.10.2975","article-title":"Urokinase receptors promote \u03b21 integrin function through interactions with integrin \u03b13\u03b21","volume":"12","author":"Wei","year":"2001","journal-title":"Mol. Biol. Cell."},{"key":"10.1016\/bs.acc.2024.04.005_bib115","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1074\/jbc.M008220200","article-title":"Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction","volume":"276","author":"Tarui","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib116","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1097\/TP.0000000000000914","article-title":"Recurrent primary focal segmental glomerulosclerosis managed with intensified plasma exchange and concomitant monitoring of soluble urokinase-type plasminogen activator receptor-mediated podocyte \u03b23-integrin activation","volume":"99","author":"Staeck","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/bs.acc.2024.04.005_bib117","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nm.4362","article-title":"A tripartite complex of suPAR, APOL1 risk variants and \u03b1v\u03b23 integrin on podocytes mediates chronic kidney disease","volume":"23","author":"Hayek","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib118","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.12100720","article-title":"Effect of sickle cell trait and APOL1 genotype on the association of soluble uPAR with kidney function measures in black americans","volume":"16","author":"Reiner","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2024.04.005_bib119","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2024.04.005_bib120","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1002\/ehf2.13497","article-title":"Integrins in cardiac hypertrophy: lessons learned from culture systems","volume":"8","author":"Bildyug","year":"2021","journal-title":"ESC. Heart Fail."},{"key":"10.1016\/bs.acc.2024.04.005_bib121","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1172\/JCI64216","article-title":"Integrins protect cardiomyocytes from ischemia\/reperfusion injury","volume":"123","author":"Okada","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib122","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/hh1101.091862","article-title":"Integrins and the myocardium","volume":"88","author":"Ross","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2024.04.005_bib123","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2741\/3381","article-title":"Integrins and proximal signaling mechanisms in cardiovascular disease","volume":"14","author":"Lal","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/bs.acc.2024.04.005_bib124","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/hh0402.105790","article-title":"Cardiac myocyte-specific excision of the \u03b21 integrin gene results in myocardial fibrosis and cardiac failure","volume":"90","author":"Shai","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/bs.acc.2024.04.005_bib125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/ijms141020597","article-title":"The epidermal growth factor receptor and its ligands in cardiovascular disease","volume":"14","author":"Makki","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2024.04.005_bib126","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1074\/jbc.M210877200","article-title":"Epidermal growth factor receptor-dependent and-independent cell-signaling pathways originating from the urokinase receptor","volume":"278","author":"Jo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.005_bib127","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jcp.20262","article-title":"Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice","volume":"204","author":"Gu","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib128","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158788","article-title":"Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis","volume":"132","author":"Hindy","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10517-022-05480-9","article-title":"Deficiency of urokinase-type plasminogen activator receptor is associated with the development of perivascular fibrosis in mouse heart","volume":"173","author":"Dergilev","year":"2022","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib130","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/annrheumdis-2015-207803","article-title":"Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice","volume":"75","author":"Manetti","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2024.04.005_bib131","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000353310","article-title":"Role of uPA\/uPAR in the modulation of angiogenesis","volume":"99","author":"Montuori","year":"2014","journal-title":"Chem. Immunol. Allergy."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.005_bib132","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00395-017-0662-x","article-title":"The RISK pathway and beyond","volume":"113","author":"Rossello","year":"2018","journal-title":"Basic. Res. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib133","doi-asserted-by":"crossref","first-page":"133","DOI":"10.14740\/jocmr4459","article-title":"Soluble urokinase plasminogen activator receptor as a diagnostic and prognostic biomarker in cardiac disease","volume":"13","author":"Velissaris","year":"2021","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/bs.acc.2024.04.005_bib134","first-page":"1293","article-title":"suPAR: a new biomarker for cardiovascular disease?","volume":"31","author":"Hodges","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib135","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015452","article-title":"Cardio-Renal biomarker soluble urokinase-type plasminogen activator receptor is associated with cardiovascular death and myocardial infarction in patients with coronary artery disease independent of troponin, c-reactive protein, and renal function","volume":"9","author":"Nikorowitsch","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/bs.acc.2024.04.005_bib136","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13867","article-title":"Prognostic value of soluble urokinase\u2010type plasminogen activator receptor in coronary artery disease: a meta\u2010analysis","volume":"52","author":"Li","year":"2022","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib137","doi-asserted-by":"crossref","first-page":"102","DOI":"10.15420\/cfr.2015.1.2.102","article-title":"Role of cardiac troponin levels in acute heart failure","volume":"1","author":"Wettersten","year":"2015","journal-title":"Card. Fail. Rev."},{"key":"10.1016\/bs.acc.2024.04.005_bib138","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/jcp.2003.015420","article-title":"Cardiac troponins","volume":"57","author":"Sharma","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2024.04.005_bib139","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/biom9030108","article-title":"Diagnostic value of soluble urokinase-type plasminogen activator receptor in addition to high-sensitivity Troponin I in Early diagnosis of acute myocardial infarction","volume":"9","author":"S\u00f6rensen","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/bs.acc.2024.04.005_bib140","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.amjcard.2012.08.008","article-title":"Usefulness of Soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention","volume":"110","author":"Lyngb\u00e6k","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib141","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5114\/aoms.2016.63596","article-title":"Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention","volume":"15","author":"Wlaze\u0142","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/bs.acc.2024.04.005_bib142","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10741-006-9196-2","article-title":"Systemic inflammation in heart failure--the whys and wherefores","volume":"11","author":"Yndestad","year":"2006","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/bs.acc.2024.04.005_bib143","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.109.884866","article-title":"B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies","volume":"120","author":"Di Angelantonio","year":"2009","journal-title":"Circulation."},{"key":"10.1016\/bs.acc.2024.04.005_bib144","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/VHRM.S5789","article-title":"Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure","volume":"6","author":"Palazzuoli","year":"2010","journal-title":"Vasc. Health Risk. Manag."},{"key":"10.1016\/bs.acc.2024.04.005_bib145","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.4065\/mcp.2011.0437","article-title":"Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study","volume":"86","author":"McKie","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/bs.acc.2024.04.005_bib146","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cardfail.2022.08.010","article-title":"Soluble urokinase plasminogen activator receptor levels and outcomes in patients with heart failure","volume":"29","author":"Hayek","year":"2023","journal-title":"J. Card. Fail."},{"key":"10.1016\/bs.acc.2024.04.005_bib147","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1515\/cclm-2020-0903","article-title":"Long term pronostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score","volume":"59","author":"Dupuy","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170546","article-title":"Serum soluble urokinase-type plasminogen activator receptor is associated with low left ventricular ejection fraction and elevated plasma brain-type natriuretic peptide level","volume":"12","author":"Fujita","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2024.04.005_bib149","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/jcm8070924","article-title":"New cardiovascular biomarkers in ischemic heart disease\u2014GDF-15, a probable predictor for ejection fraction","volume":"8","author":"Dalos","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejim.2017.05.027","article-title":"A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure","volume":"44","author":"Lichtenauer","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib151","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1002\/ehf2.14071","article-title":"Biomarker prognostication across universal definition of heart failure stages","volume":"9","author":"Mohebi","year":"2022","journal-title":"ESC. Heart Fail."},{"key":"10.1016\/bs.acc.2024.04.005_bib152","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2024.04.005_bib153","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2024.04.005_bib154","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.xkme.2021.04.007","article-title":"Variability in CKD biomarker studies: soluble urokinase plasminogen activator receptor (suPAR) and kidney disease progression in the chronic kidney disease in children (ckid) study","volume":"3","author":"Abraham","year":"2021","journal-title":"Kidney Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib155","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble urokinase receptor and chronic kidney disease","volume":"373","author":"Hayek","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib156","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ndt\/gfy265","article-title":"Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease","volume":"35","author":"Lv","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/bs.acc.2024.04.005_bib157","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2215\/CJN.13631217","article-title":"Soluble urokinase-type plasminogen activator receptor in black americans with CKD","volume":"13","author":"Luo","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2024.04.005_bib158","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1911481","article-title":"Soluble urokinase receptor and acute kidney injury","volume":"382","author":"Hayek","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib159","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib160","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1681\/ASN.2013040425","article-title":"Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice","volume":"25","author":"Cathelin","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2024.04.005_bib161","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1053\/j.jvca.2020.10.049","article-title":"Prognostic value of soluble urokinase-type plasminogen activator receptor and high-sensitivity c-reactive protein on postoperative mortality in patients undergoing elective on-pump cardiac surgery","volume":"35","author":"Rasmussen","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/bs.acc.2024.04.005_bib162","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/00365513.2021.1990395","article-title":"Impact of cardiopulmonary bypass and surgical complexity on plasma soluble urokinase-type plasminogen activator receptor levels after cardiac surgery","volume":"81","author":"Dardashti","year":"2021","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib163","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/icvts\/ivaa239","article-title":"Can soluble urokinase plasminogen receptor predict outcomes after cardiac surgery?","volume":"32","author":"Schultz-Swarthfigure","year":"2021","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.005_bib164","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12882-021-02322-0","article-title":"Prognostic value of suPAR and hsCRP on acute kidney injury after cardiac surgery","volume":"22","author":"Rasmussen","year":"2021","journal-title":"BMC Nephrol."},{"key":"10.1016\/bs.acc.2024.04.005_bib165","first-page":"494","article-title":"GDF-15 as a biomarker in cardiovascular disease","volume":"116","author":"May","year":"2021","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/bs.acc.2024.04.005_bib166","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation factor-15 (GDF-15):\u00a0from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.acc.2024.04.005_bib167","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1432-1327.1999.00615.x","article-title":"Different promoter usage and multiple transcription initiation sites of the interleukin\u20101 receptor\u2010related human ST2 gene in UT\u20107 and TM12 cells","volume":"264","author":"Iwahana","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/bs.acc.2024.04.005_bib168","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cca.2014.09.021","article-title":"Soluble ST2 in heart failure","volume":"443","author":"Dieplinger","year":"2015","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/bs.acc.2024.04.005_bib169","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/jcm9010164","article-title":"Heart-Type fatty acid-binding protein (H-FABP) and its role as a biomarker in heart failure: what do we know so far?","volume":"9","author":"Rezar","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib170","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/jcm9041130","article-title":"Expression of the novel cardiac biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients compared to ICM, DCM, and controls","volume":"9","author":"Jirak","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib171","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/aps.2017.167","article-title":"Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure","volume":"39","author":"Jirak","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/bs.acc.2024.04.005_bib172","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.peptides.2004.06.019","article-title":"Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients","volume":"25","author":"Struck","year":"2004","journal-title":"Peptides"},{"issue":"Supplement_2","key":"10.1016\/bs.acc.2024.04.005_bib173","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.1087","article-title":"Comparative performances of soluble urokinase plasminogen activator receptor and Mid-regional proADM to predict composite death and new heart failure rehospitalisation in acutely breathless patients","volume":"43","author":"Chew-Harris","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2024.04.005_bib174","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13867","article-title":"Prognostic value of soluble urokinase-type plasminogen activator receptor in coronary artery disease: a meta-analysis","volume":"52","author":"Li","year":"2022","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/bs.acc.2024.04.005_bib175","first-page":"S86","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in patients with acute chest pain","volume":"30","author":"Chew-Harris","year":"2021","journal-title":"Heart Lung Circ."},{"key":"10.1016\/bs.acc.2024.04.005_bib176","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1590\/s1806-37562017000000151","article-title":"Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD","volume":"44","author":"AboEl-Magd","year":"2018","journal-title":"J. Bras. Pneumol."},{"key":"10.1016\/bs.acc.2024.04.005_bib177","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin\u20101 Blockade inhibits the acute inflammatory response in patients With ST\u2010segment\u2013elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/bs.acc.2024.04.005_bib178","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib179","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2024.04.005_bib180","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1616105","article-title":"Release of soluble urokinase receptor from vascular cells","volume":"86","author":"Chavakis","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2024.04.005_bib181","unstructured":"ViroGates. suPARnostic is prognostic across diseases.\u00a0https:\/\/www.virogates.com\/supar-across-diseases\/,\u00a02022\u00a0(accessed\u00a018.11.23)."},{"key":"10.1016\/bs.acc.2024.04.005_bib182","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.atherosclerosis.2018.03.030","article-title":"Effect of simvastatin and ezetimibe on suPAR levels and outcomes","volume":"272","author":"Hodges","year":"2018","journal-title":"Atherosclerosis"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242324000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242324000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:01:51Z","timestamp":1753430511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242324000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443297021"],"references-count":182,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2024.04.005","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}